We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Abbott Diagnostics

Abbott Diagnostics provides medical diagnostic instruments, tests, automation and informatics solutions, including cl... read more Featured Products: More products

Download Mobile App





Abbott Displays Its Life-Changing POC Tests and Diagnostic Tools at MEDLAB Middle East

By LabMedica International staff writers
Posted on 26 Jan 2022

At the 2022 edition of MEDLAB Middle East, Abbott (Lake Forest, IL, USA) showcased its portfolio of life-changing diagnostic tools and medical devices for point-of-care testing that help manage patients with COVID-19, diabetes cardiovascular disease and their comorbidities. More...

Within its COVID-19 test portfolio, Abbott displayed its ID NOW COVID-19 molecular point-of-care platform that combines the benefits of speed and accuracy for the fastest molecular results in the market. The ID NOW COVID-19 test returns positive results in 13 minutes or less to enable immediate clinical decisions during the first patient visit. The easy to use ID NOW platform is designed for near-patient, point-of-care use in a variety of healthcare settings. Abbott highlighted its Panbio COVID-19 IgG/IgM Rapid Test Device, an in vitro diagnostic rapid test for the qualitative detection of IgG and IgM antibodies to SARS-CoV-2 in human serum, plasma, venous and fingerstick whole blood, alongside the Panbio COVID-19 Ag Rapid Test Device which can identify potentially contagious patients with or without symptoms in 15 minutes.

Also on display was the Afinion 2 System, a compact, rapid, multi-assay analyzer that provides valuable near patient testing at the point-of-care for physician offices and clinics, eliminating the need to send patients to the lab or spend time tracking down their results. The Afinion 2 System makes it fast and easy to test quantitative determinations of HbA1c, Lipid Panel, ACR, and CRP, and can reliably transfer test information to a HIS or LIS system. The analyzer and test cartridges have been precision engineered with each test cartridge containing an integrated sample collection device and all necessary reagents for a single test.

At MEDLAB 2022, Abbott demonstrated the i-STAT Family of products for a broad range of clinical settings, including the lightweight, portable and easy to use i-STAT 1 blood analyzer which operates with the advanced technology of i-STAT test cartridges. Together, they create the i-STAT System - a point-of-care testing platform that provides healthcare professionals with diagnostic information when and where it's needed. Abbott also displayed the i-STAT Alinity, an easy-in-use, portable bloody analyzer that delivers real-time, lab-quality diagnostic test results. The i-STAT Alinity is the i-STAT family's most advanced testing solution and features a more intuitive interface that simplifies the testing process even further, allowing for minimal operator training.

Related Links:
Abbott 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
POC Immunoassay Analyzer
Procise DX
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.